Genetic-epigenetic tissue mapping for plasma DNA: applications in prenatal testing, transplantation and oncology

  1. Wanxia Gai
  2. Ze Zhou
  3. Sean Agbor-Enoh
  4. Xiaodan Fan
  5. Sheng Lian
  6. Peiyong Jiang
  7. Suk Hang Cheng
  8. John Wong
  9. Stephen Lam Chan
  10. Moon Kyoo Jang
  11. Yanqin Yang
  12. Raymond H S Liang
  13. Wai Kong Chan
  14. Edmond S K Ma
  15. Tak Y Leung
  16. Rossa W K Chiu
  17. Hannah Valantine
  18. K C Allen Chan
  19. Y M Dennis Lo  Is a corresponding author
  1. The Chinese University of Hong Kong, Hong Kong
  2. Johns Hopkins School of Medicine, United States
  3. National Heart, Lung and Blood Institute, United States
  4. Hong Kong Sanatorium and Hospital, Hong Kong

Abstract

We developed Genetic-Epigenetic Tissue Mapping (GETMap) to determine the tissue composition of plasma DNA carrying genetic variants not present in the constitutional genome through comparing their methylation profiles with relevant tissues. We validated this approach by showing that, in pregnant women, circulating DNA carrying fetal-specific alleles was entirely placenta-derived. In lung-transplant recipients, we showed that, at 72 hours after transplantation, the lung contributed only a median of 17% to the plasma DNA carrying donor-specific alleles and hematopoietic cells contributed a median of 78%. In hepatocellular cancer patients, the liver was identified as the predominant source of plasma DNA carrying tumor-specific mutations. In a pregnant woman with lymphoma, plasma DNA molecules carrying cancer mutations and fetal-specific alleles were accurately shown to be derived from the lymphocytes and placenta, respectively. Analysis of tissue origin for plasma DNA carrying genetic variants is potentially useful for noninvasive prenatal testing, transplantation monitoring and cancer screening.

Data availability

Sequencing data have been deposited in EGA under the accession code EGAS00001004788.

The following data sets were generated

Article and author information

Author details

  1. Wanxia Gai

    Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
    Competing interests
    No competing interests declared.
  2. Ze Zhou

    Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
    Competing interests
    No competing interests declared.
  3. Sean Agbor-Enoh

    Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, United States
    Competing interests
    No competing interests declared.
  4. Xiaodan Fan

    Department of Statistics, The Chinese University of Hong Kong, Shatin, Hong Kong
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-2744-9030
  5. Sheng Lian

    Statistics, The Chinese University of Hong Kong, Shatin, Hong Kong
    Competing interests
    No competing interests declared.
  6. Peiyong Jiang

    Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
    Competing interests
    Peiyong Jiang, Holds equities in Grail.Serves as a director of KingMed Future.Received patent royalties from Grail, Illumina, Sequenom, DRA, Take2 and Xcelom.Filed a patent application (US15/214,998)..
  7. Suk Hang Cheng

    Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
    Competing interests
    No competing interests declared.
  8. John Wong

    Surgery, The Chinese University of Hong Kong, Shatin, Hong Kong
    Competing interests
    No competing interests declared.
  9. Stephen Lam Chan

    Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, Hong Kong
    Competing interests
    No competing interests declared.
  10. Moon Kyoo Jang

    Division of Intramural Research, National Heart, Lung and Blood Institute, Bethesda, United States
    Competing interests
    No competing interests declared.
  11. Yanqin Yang

    Division of Intramural Research, National Heart, Lung and Blood Institute, Bethesda, United States
    Competing interests
    No competing interests declared.
  12. Raymond H S Liang

    Comprehensive Oncology Centre, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
    Competing interests
    No competing interests declared.
  13. Wai Kong Chan

    Pathology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
    Competing interests
    No competing interests declared.
  14. Edmond S K Ma

    Pathology, Hong Kong Sanatorium and Hospital, Happy Valley, Hong Kong
    Competing interests
    No competing interests declared.
  15. Tak Y Leung

    Obstetrics and Gynaecology, The Chinese University of Hong Kong, Shatin, Hong Kong
    Competing interests
    No competing interests declared.
  16. Rossa W K Chiu

    Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
    Competing interests
    Rossa W K Chiu, Holds equities in DRA, Take2 and Grail.Is a consultant to Grail and Illumina.Receives research funding from Grail.Receives royalties from Grail, Illumina, Sequenom, DRA, Take2 and Xcelom.Filed a patent application (US15/214,998)..
  17. Hannah Valantine

    Division of Intramural Research, National Heart, Lung and Blood Institute, Bethesda, United States
    Competing interests
    No competing interests declared.
  18. K C Allen Chan

    Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong
    Competing interests
    K C Allen Chan, Holds equities in DRA, Take2 and Grail.Is a consultant to and receives research funding from Grail.Receives royalties from Grail, Illumina, Sequenom, DRA, Take2 and Xcelom.Filed a patent application (US15/214,998)..
  19. Y M Dennis Lo

    Department of Chemical Pathology, The Chinese University of Hong Kong, Hong Kong, Hong Kong
    For correspondence
    loym@cuhk.edu.hk
    Competing interests
    Y M Dennis Lo, Reviewing editor, eLife.Holds equities in DRA, Take2 and Grail.Is a consultant, scientific cofounder and scientific advisory board member of Grail.Received patent royalties from Grail, Illumina, Sequenom, DRA, Take2 and Xcelom.Had filed a patent application (US15/214,998)..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8746-0293

Funding

Research Grants Council, University Grants Committee (Theme-based research scheme T12-403/15-N)

  • Rossa W K Chiu
  • K C Allen Chan
  • Y M Dennis Lo

Research Grants Council, University Grants Committee (Theme-based research scheme T12-401/16-W)

  • Rossa W K Chiu
  • K C Allen Chan
  • Y M Dennis Lo

Chinese University of Hong Kong (VCF2014021)

  • Rossa W K Chiu
  • K C Allen Chan
  • Y M Dennis Lo

Grail (Collaborative research agreement)

  • Rossa W K Chiu
  • K C Allen Chan
  • Y M Dennis Lo

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The project was approved by the Joint Chinese University of Hong Kong-Hospital Authority New Territories East Cluster Clinical Research Ethics Committee (approval reference number 2011.204). All participants provided written informed consent.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 2,880
    views
  • 402
    downloads
  • 22
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Wanxia Gai
  2. Ze Zhou
  3. Sean Agbor-Enoh
  4. Xiaodan Fan
  5. Sheng Lian
  6. Peiyong Jiang
  7. Suk Hang Cheng
  8. John Wong
  9. Stephen Lam Chan
  10. Moon Kyoo Jang
  11. Yanqin Yang
  12. Raymond H S Liang
  13. Wai Kong Chan
  14. Edmond S K Ma
  15. Tak Y Leung
  16. Rossa W K Chiu
  17. Hannah Valantine
  18. K C Allen Chan
  19. Y M Dennis Lo
(2021)
Genetic-epigenetic tissue mapping for plasma DNA: applications in prenatal testing, transplantation and oncology
eLife 10:e64356.
https://doi.org/10.7554/eLife.64356

Share this article

https://doi.org/10.7554/eLife.64356

Further reading

    1. Medicine
    2. Microbiology and Infectious Disease
    Kavidha Reddy, Guinevere Q Lee ... Thumbi Ndung'u
    Research Article

    Persisting HIV reservoir viruses in resting CD4 T cells and other cellular subsets are a barrier to cure efforts. Early antiretroviral therapy (ART) enables post-treatment viral control in some cases, but mechanisms remain unclear. We hypothesised that ART initiated before peak viremia impacts HIV-1 subtype C reservoirs. We studied 35 women at high risk of infection from Durban, South Africa, identified with hyperacute HIV by twice-weekly HIV-RNA testing. Participants included 11 starting ART at a median of 456 (297–1203) days post-onset of viremia (DPOV) and 24 at 1 (1–3) DPOV. Peripheral blood mononuclear cells (PBMCs) were used to measured total HIV-1 DNA by droplet digital PCR (ddPCR) and sequence viral reservoir genomes by full-length proviral sequencing (FLIP-seq). ART during hyperacute infection blunted peak viremia (p<0.0001), but contemporaneous total HIV-1 DNA did not differ (p=0.104). Over 1 year, a decline of total HIV-1 DNA was observed in early treated persons (p=0.0004), but not late treated. Among 697 viral genome sequences, the proviral genetic landscape differed between untreated, late treated, and early treated groups. Intact genomes after 1 year were higher in untreated (31%) versus late treated (14%) and early treated (0%). Treatment in both late and early infection caused more rapid decay of intact (13% and 51% per month) versus defective (2% and 35%) viral genomes. However, intact genomes persisted 1 year post chronic treatment but were undetectable with early ART. Early ART also reduced phylogenetic diversity of intact genomes and limited cytotoxic T lymphocyte immune escape variants in the reservoir. Overall, ART initiated in hyperacute HIV-1 subtype C infection did not impact reservoir seeding but was associated with rapid intact viral genome decay, reduced genetic complexity, and limited immune escape, which may accelerate reservoir clearance in combination with other interventional strategies.

    1. Cancer Biology
    2. Medicine
    Patrick Brandt, Dawayne Whittington ... Rebekah L Layton
    Research Article

    A doctoral-level internship program was developed at the University of North Carolina at Chapel Hill with the intent to create customizable experiential learning opportunities for biomedical trainees to support career exploration, preparation, and transition into their postgraduate professional roles. We report the outcomes of this program over a 5-year period. During that 5-year period, 123 internships took place at over 70 partner sites, representing at least 20 academic, for-profit, and non-profit career paths in the life sciences. A major goal of the program was to enhance trainees’ skill development and expertise in careers of interest. The benefits of the internship program for interns, host/employer, and supervisor/principal investigator were assessed using a mixed-methods approach, including surveys with closed- and open-ended responses as well as focus group interviews. Balancing stakeholder interests is key to creating a sustainable program with widespread support; hence, the level of support from internship hosts and faculty members were the key metrics analyzed throughout. We hypothesized that once a successful internship program was implemented, faculty culture might shift to be more accepting of internships; indeed, the data quantifying faculty attitudes support this. Furthermore, host motivation and performance expectations of interns were compared with results achieved, and this data revealed both expected and surprising benefits to hosts. Data suggests a myriad of benefits for each stakeholder group, and themes are cataloged and discussed. Program outcomes, evaluation data, policies, resources, and best practices developed through the implementation of this program are shared to provide resources that facilitate the creation of similar internship programs at other institutions. Program development was initially spurred by National Institutes of Health pilot funding, thereafter, successfully transitioning from a grant-supported model, to an institutionally supported funding model to achieve long-term programmatic sustainability.